Drug · CHEMBL609
TRIENTINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. TRIENTINE. Drugs and targets, record CHEMBL609. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL609
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- NSC-443, Trethylenetetramine, Trientina, Triethylene tetraamine, Triethylene tetramine
- ChEMBL
- Open Targets' highest stage
- Approval, for 2 of its 8 diseases, from EMA Human Drugs and TTD
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases8
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| Wilson disease | Approval | EMA Human Drugs | 8 | 7 | https://conductscience.org/library/drugs?q=MONDO_0010200 |
| fallopian tube cancer | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0002158 |
| hypertrophic cardiomyopathy | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005045 |
| malignant epithelial tumor of ovary | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0018364 |
| melanoma | Phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005105 |
| ovarian carcinoma | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005140 |
| primary peritoneal carcinoma | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0015686 |
| inborn errors of metabolism | Approval | TTD | 1 | 0 | https://conductscience.org/library/drugs?q=MONDO_0019052 |
Source Open Targets
Trials13
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT06128954 | Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily). | Phase 1 | 26 | 2025-08-15 | trientine | Its name | ClinicalTrials.gov |
| NCT03480750 | Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer | Phase 1/2 | 18 | 2020-11-10 | trientine | Its name | ClinicalTrials.gov |
| NCT01472874 | Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease | 8 | 2014-05-19 | trientine | Its name | ClinicalTrials.gov | |
| NCT02763215 | The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment | 64 | 2020-10-26 | trientine | Its name | ClinicalTrials.gov | |
| NCT04706429 | The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy | Phase 2 | 154 | trientine | Its name | ClinicalTrials.gov | |
| NCT00004339 | Study of Tetrathiomolybdate in Patients With Wilson Disease | Phase 3 | 90 | trientine | Its name | ClinicalTrials.gov | |
| NCT02426905 | Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine | Phase 4 | 90 | trientine dihydrochloride | The name of another form of it | ClinicalTrials.gov | |
| NCT01178112 | Trientine and Carboplatin in Advanced Malignancies | Phase 1 | 56 | trientine | Its name | ClinicalTrials.gov | |
| NCT01874028 | A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson's Disease Patients | Phase 1 | 20 | trientine dihydrochloride | The name of another form of it | ClinicalTrials.gov | |
| NCT07010575 | Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride | Phase 2 | 10 | trientine | Its name | ClinicalTrials.gov |
1 to 10 of 13
See all 13 trialsComparisons in its trials2
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Once Daily Dose Formulation (Treatment A) vs Cuprior® Comparator (Treatment B): deaths from any cause | 0 of 26 | 0 of 26 | 52 | NCT06128954 | Trial comparisons |
| Once Daily Dose Formulation (Treatment A) vs Cuprior® Comparator (Treatment B): serious adverse events | 0 of 26 | 0 of 26 | 52 | NCT06128954 | Trial comparisons |
Papers from its trials7
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL609
GET https://conductscience.org/api/drugs/v1/CHEMBL609/targets